ZA201702483B - Combination therapies with anti-cd38 antibodies - Google Patents

Combination therapies with anti-cd38 antibodies

Info

Publication number
ZA201702483B
ZA201702483B ZA2017/02483A ZA201702483A ZA201702483B ZA 201702483 B ZA201702483 B ZA 201702483B ZA 2017/02483 A ZA2017/02483 A ZA 2017/02483A ZA 201702483 A ZA201702483 A ZA 201702483A ZA 201702483 B ZA201702483 B ZA 201702483B
Authority
ZA
South Africa
Prior art keywords
antibodies
combination therapies
therapies
combination
Prior art date
Application number
ZA2017/02483A
Other languages
English (en)
Inventor
Henk M Lokhorst
Tuna Mutis
Inger S Nijhof
De Donk Niels W Van
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201702483(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ZA201702483B publication Critical patent/ZA201702483B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2017/02483A 2014-09-09 2017-04-07 Combination therapies with anti-cd38 antibodies ZA201702483B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462047877P 2014-09-09 2014-09-09
US201462087287P 2014-12-04 2014-12-04
PCT/US2015/048899 WO2016040294A2 (en) 2014-09-09 2015-09-08 Combination therapies with anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
ZA201702483B true ZA201702483B (en) 2019-09-25

Family

ID=55436472

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/02483A ZA201702483B (en) 2014-09-09 2017-04-07 Combination therapies with anti-cd38 antibodies

Country Status (25)

Country Link
US (2) US20160067205A1 (enExample)
EP (1) EP3191187B1 (enExample)
JP (2) JP6707531B2 (enExample)
KR (1) KR102586588B1 (enExample)
CN (1) CN108064182B (enExample)
AU (1) AU2015315396B2 (enExample)
BR (1) BR112017004614A2 (enExample)
CA (1) CA2960494C (enExample)
CL (1) CL2017000559A1 (enExample)
CR (1) CR20170086A (enExample)
EA (1) EA035979B1 (enExample)
EC (1) ECSP17021175A (enExample)
ES (1) ES2890669T3 (enExample)
GT (1) GT201700048A (enExample)
IL (1) IL251033B (enExample)
MA (1) MA40608A (enExample)
MX (1) MX386886B (enExample)
MY (1) MY192918A (enExample)
NI (1) NI201700027A (enExample)
PE (1) PE20170676A1 (enExample)
PH (1) PH12017500442B1 (enExample)
SG (1) SG11201701867SA (enExample)
UA (1) UA122212C2 (enExample)
WO (1) WO2016040294A2 (enExample)
ZA (1) ZA201702483B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296666A (en) * 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN110981964B (zh) 2013-01-14 2023-09-15 Xencor股份有限公司 新型异二聚体蛋白
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
MX384025B (es) 2014-11-26 2025-03-14 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PE20171103A1 (es) 2014-11-26 2017-08-07 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
RS61668B1 (sr) 2015-05-13 2021-04-29 Morphosys Ag Lečenje multiplog mijeloma (mm)
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
PT3370770T (pt) 2015-11-03 2021-02-22 Janssen Biotech Inc Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
TWI724046B (zh) * 2016-04-06 2021-04-11 美商健生生物科技公司 以抗ｃｄ３８抗體與生存素抑制劑於血紅素惡性腫瘤之組合治療
DK3468586T3 (da) 2016-06-14 2024-10-21 Xencor Inc Bispecifikke checkpoint-hæmmer-antistoffer
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
JP7316930B2 (ja) 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
TW201823471A (zh) * 2016-10-06 2018-07-01 美商錫羅斯製藥公司 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3703749A1 (en) 2017-10-31 2020-09-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
EP3706793A1 (en) 2017-11-08 2020-09-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
WO2019094931A1 (en) * 2017-11-10 2019-05-16 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
AU2019208102B2 (en) 2018-01-12 2025-10-09 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN113710706A (zh) 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
AR120054A1 (es) 2019-06-10 2022-02-02 Takeda Pharmaceuticals Co Politerapias con anticuerpos de cd-38
KR20220092580A (ko) 2019-11-06 2022-07-01 제넨테크, 인크. 혈액암의 치료를 위한 진단과 치료 방법
GB201916150D0 (en) * 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
KR20230082632A (ko) 2020-10-05 2023-06-08 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
KR20240169042A (ko) 2022-04-01 2024-12-02 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202417042A (zh) 2022-07-13 2024-05-01 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
CN119604530A (zh) 2022-07-19 2025-03-11 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
IL320355A (en) 2022-10-25 2025-06-01 Genentech Inc Therapeutic and diagnostic methods for multiple myeloma
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
IE912466A1 (en) 1990-07-13 1992-01-15 Gen Hospital Corp Rapid immunoselection cloning method
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP4233608B2 (ja) 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
EP0932417B1 (en) 1996-10-17 2003-03-05 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
DE69831224T2 (de) 1997-05-02 2006-03-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) * 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU2001265418B2 (en) 2000-06-22 2006-03-30 Biogen Idec Inc. Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
EP1326998A4 (en) 2000-10-17 2005-05-11 Trudeau Inst Inc MODIFIED CHEMOTAXIS GENE CD38
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
AU2003257419B2 (en) * 2002-06-13 2010-02-25 Crucell Holland, B.V. OX40 (CD134) receptor agonistic and therapeutic use
EP2177620B1 (en) 2003-03-05 2014-11-19 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1689435A4 (en) 2003-10-22 2007-10-03 Univ Rochester ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
EP1684805B8 (en) 2003-11-04 2010-08-25 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
RS54056B1 (sr) 2004-02-06 2015-10-30 Morphosys Ag Anti-cd38 humana antitela i njihove upotrebe
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
IL296666A (en) * 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
ES2653664T3 (es) 2005-10-12 2018-02-08 Morphosys Ag Generación y caracterización de anticuerpos terapéuticos obtenidos mediante HuCal GOLD completamente humanos específicos de CD38 humano
CA2632698A1 (en) 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using cd40 binding agents
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2049109B1 (en) 2006-08-02 2015-11-18 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
LT2081595T (lt) 2006-09-26 2019-07-10 Genmab A/S Anti-cd38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
JP2010529024A (ja) 2007-06-01 2010-08-26 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ結合分子
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
EP2211902A1 (en) 2007-11-09 2010-08-04 Novartis AG Uses of anti-cd40 antibodies
EP2237798A2 (en) 2007-12-12 2010-10-13 Imperial Innovations Limited Methods
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2009111508A2 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
CA2716884C (en) 2008-03-25 2017-10-03 Charles Dumontet Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
CN103381267A (zh) 2008-04-14 2013-11-06 哈洛齐梅公司 修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2010052014A1 (en) 2008-11-07 2010-05-14 Micromet Ag Treatment of acute lymphoblastic leukemia
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
US20130137134A1 (en) 2010-03-29 2013-05-30 Ben Gurion University Of The Negev Research And Development Authority Method and system for detecting and monitoring hematological cancer
EA201201435A1 (ru) 2010-04-20 2013-04-30 Генмаб А/С ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
LT2621531T (lt) * 2010-09-27 2017-04-10 Morphosys Ag Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
CA2815266C (en) 2010-11-05 2023-09-05 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
CL2013001944A1 (es) 2010-12-30 2014-09-12 Takeda Pharmaceutical Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2543569T3 (es) 2011-03-23 2015-08-20 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
BR112014009925B1 (pt) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
IL318221A (en) 2012-05-15 2025-03-01 Bristol Myers Squibb Co Cancer immunotherapy by disrupting PD–1/PD–L1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
LT2900232T (lt) * 2012-09-25 2018-02-26 Morphosys Ag Deriniai ir jų panaudojimas
ES2621377T3 (es) 2012-11-05 2017-07-03 Morphosys Ag Anticuerpo marcado radiactivamente y usos del mismo
WO2014142220A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US20140271644A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
US20140356318A1 (en) 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
US20160235842A1 (en) 2013-07-15 2016-08-18 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists
SG10201803288RA (en) 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
EP3066125A2 (en) 2013-11-06 2016-09-14 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015195556A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
CA2990620A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
PT3370770T (pt) 2015-11-03 2021-02-22 Janssen Biotech Inc Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
EP3703749A1 (en) 2017-10-31 2020-09-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Also Published As

Publication number Publication date
PH12017500442B1 (en) 2023-05-24
MA40608A (fr) 2016-03-17
JP2017528462A (ja) 2017-09-28
US20170107295A1 (en) 2017-04-20
PH12017500442A1 (en) 2017-07-31
KR102586588B1 (ko) 2023-10-06
CN108064182B (zh) 2021-09-03
EP3191187A2 (en) 2017-07-19
HK1255599A1 (zh) 2019-08-23
ES2890669T3 (es) 2022-01-21
CA2960494C (en) 2022-11-08
US20160067205A1 (en) 2016-03-10
SG11201701867SA (en) 2017-04-27
NZ729816A (en) 2024-08-30
MX386886B (es) 2025-03-12
WO2016040294A3 (en) 2016-06-02
NI201700027A (es) 2017-06-22
JP2020143108A (ja) 2020-09-10
KR20170054442A (ko) 2017-05-17
GT201700048A (es) 2019-08-21
CR20170086A (es) 2017-05-22
AU2015315396A1 (en) 2017-03-30
US10604580B2 (en) 2020-03-31
AU2015315396B2 (en) 2020-10-08
MY192918A (en) 2022-09-15
PE20170676A1 (es) 2017-05-22
WO2016040294A2 (en) 2016-03-17
MX2017003115A (es) 2017-11-17
EP3191187B1 (en) 2021-07-28
EA201790548A1 (ru) 2017-09-29
CL2017000559A1 (es) 2018-02-16
UA122212C2 (uk) 2020-10-12
ECSP17021175A (es) 2018-07-31
IL251033A0 (en) 2017-04-30
BR112017004614A2 (pt) 2018-02-27
CN108064182A (zh) 2018-05-22
EP3191187A4 (en) 2018-04-04
CA2960494A1 (en) 2016-03-17
JP6707531B2 (ja) 2020-06-10
EA035979B1 (ru) 2020-09-08
IL251033B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
ZA201708541B (en) Combination therapies with anti-cd38 antibodies
ZA201702483B (en) Combination therapies with anti-cd38 antibodies
IL250512B (en) Combined treatments with antibodies against cd40
IL252442A0 (en) Combined treatments
IL250583A0 (en) Anti-tigit antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
IL250374A0 (en) Antibodies against ceramide
IL247988A0 (en) Antibodies against hpa–1a
EP3129022A4 (en) Combination therapies with curaxins
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies
GB201413745D0 (en) Antibody